Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Slides:

Advertisements

Similar presentations

Dose-escalation patient response.

Advertisements

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

A B C D Supplementary Figure 1 CMV p300

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

MAPK pathway inhibitors.

BRAF inhibitor: targeted therapy in hairy cell leukemia

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.

MEL23 and MEL24 inhibit Mdm2 and p53 ubiquitination in cells.

Pirh2 promotes p73 ubiquitination in vivo.

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

Volume 28, Issue 3, Pages (September 2015)

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

RAS/RAF pathway-activated ovarian cancer cells exhibit MEK dependence and synergistic induction of apoptosis with combined MEK/AKT inhibition. RAS/RAF.

AKT dependence of ovarian cancer cell lines.

APCFZR1 promotes BRAF ubiquitination in a D-box–dependent manner.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

NF1 downregulation activates MAPK pathway signaling.

A20 inhibits caspase-8 cleavage and TRAIL-induced apoptosis.

Downregulation of SPRY4 expression is associated with FGFR1–FRS2 activation. Downregulation of SPRY4 expression is associated with FGFR1–FRS2 activation.

Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.

KIF1Bβ promotes DHX9 nuclear localization.

Activated membrane signaling promotes survival in response to radiation. Activated membrane signaling promotes survival in response to radiation. Radiation.

An siRNA screen identifies BER pathway members as sensitizers to temozolomide (TMZ) in pediatric GBM. A and B, SJG2 and KNS42 cells were transfected with.

p38 MAPK activation is required for phosphorylation of Akt at Ser473.

Leto et al., Supplementary Figure S3

AMPK induces VEGF-A production by upregulating ERK signaling.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

ROS induction and ATR inhibition synergize in inducing multiple myeloma (MM) cell death. ROS induction and ATR inhibition synergize in inducing multiple.

Fig. 3. Inactivation of the Wnt/β-catenin signaling pathway inhibited cell proliferation and induced apoptosis in A549 and SPC-A-1 cells. Inactivation.

mTORC1- and mTORC2-activating mutations in MTOR and RHEB

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Synergistic WNT1 and WNT7B signaling is downstream of LRP6 phosphorylation and β-catenin stabilization. Synergistic WNT1 and WNT7B signaling is downstream.

The p53 pathway is involved in the inhibition of cell proliferation observed in 15-LOX-1-overexpressing cells. The p53 pathway is involved in the inhibition.

BEZ235 induces MAPK signaling in a FOXO3A-dependent manner.

Effect of GSK-3β inhibition on cell-confluence-induced apoptosis.

Effect of LY on phosphorylation of various MAP kinase substrates in HeLa cells in vitro. Effect of LY on phosphorylation of various MAP kinase.

DNA damage signaling regulates mutant p53 ubiquitination.

Overexpression of Pim kinases contributes to increased protein translation in resistant cells through controlling cap-independent translation. Overexpression.

Lamellarin D induces cell death through a Fas-independent pathway.

Sensor siRNAs can be used in high-order combinations.

Expression of versican promoted breast cancer cell self-renewal through enhanced EGFR/AKT/GSK-3β (S9P) signals. Expression of versican promoted breast.

Role of MAPKs on DPP-23-induced autophagy and apoptosis.

Targeting HR via CDK inhibition resensitizes recurrent cultures to temozolomide (TMZ). Targeting HR via CDK inhibition resensitizes recurrent cultures.

Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma cells. Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma.

Replication stress inhibition synergizes with DNA damaging agents in human cells. Replication stress inhibition synergizes with DNA damaging agents in.

Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. LNCaP,

Reactivation of epigenetically silenced SMAD1 contributes to chemosensitization. Reactivation of epigenetically silenced SMAD1 contributes to chemosensitization.

Changes in signal transduction pathway induced by gefitinib.

EGFR signaling regulates transcription of PDGFRβ gene.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

The effects of AZD1775 and olaparib on DNA damage response signaling.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

PTEN-deficient prostate cancer cells exhibit constitutive macropinocytosis. PTEN-deficient prostate cancer cells exhibit constitutive macropinocytosis.

AKT activation in HCC2429 is SRC- but not Notch-dependent.

Trastuzumab resistance siRNA screen identifies PPM1H.

Effect of MIF siRNA on the production of MMP-13 induced by LPA

LUBAC is essential for NF-κB activity in ABC DLBCL

MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

Regulation of signaling by wild-type and oncogenic Ras.

EPHA2 inhibitors inhibit phosphorylation of AKT and ERK, arrest cell cycle at G0–G1, and induce apoptosis in both vemurafenib (VEM)-sensitive and VEM-resistant.

Mechanism of ERM protein–dependent CD44 cleavage.

Effects of inhibitors of PI3K, MEK1, and GSK-3β on visfatin-induced proliferation in HepG2 cells. Effects of inhibitors of PI3K, MEK1, and GSK-3β on visfatin-induced.

MEK1/2-ERK1/2-p190RHOGAP and INK4a/ARF deficiency drive RHOA activation in NSCLC. A and B, G-LISA assay showing RHOA-GTP levels in H460, A549, and H838.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

MYC is required for the hypoxic induction of SHMT2.

AXL is not necessary for maintenance of intrinsic resistance.

Presentation transcript:

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Immunoblotting of lysates from 293H cells transfected with plasmids encoding FLAG-BRAF V600E, FLAG-BRAF L597R, or FLAG-BRAF L597S show that RAF/MEK/ERK pathway signaling can be inhibited by increasing doses (0, 0.1, 0.5, 1, and 5 μmol/L) of the BRAF inhibitor vemurafenib (A) or the MEK inhibitor GSK1120212 (B), 2 hours post inhibitor treatment. BRAF L597R and L597S signaling compared to the vector control is shown in Supplementary Fig. S8. Kimberly Brown Dahlman et al. Cancer Discovery 2012;2:791-797 ©2012 by American Association for Cancer Research